# PD-L1 Inhibitor + RT ± Ursodeoxycholic Acid in Recurrent/Metastatic HER2-Neg Breast Cancer

> **NCT06842472** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 70 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Ursodeoxycholic Acid (URSO)
- **RADIATION:** Radiotherapy
- **DRUG:** Adebrelimab (PD-L1 inhibitor)

## Key facts

- **NCT ID:** NCT06842472
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02
- **Primary completion:** 2028-12
- **Final completion:** 2029-12
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06842472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06842472, "PD-L1 Inhibitor + RT ± Ursodeoxycholic Acid in Recurrent/Metastatic HER2-Neg Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06842472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*